Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Globus Medical recently disclosed its financial results for the first quarter of 2024, showcasing significant growth and strategic advancements post the integration with NuVasive.</li><li>The company reported a remarkable 119% increase in sales, reaching $607 million, and a 36% rise in non-GAAP EPS to $0.72.</li><li>This period marks the first quarter of the combined field organizations of Globus and NuVasive, underscoring a robust integration process aimed at streamlining operations and escalating market reach.</li></ul>

Globus Medical recently disclosed its financial results for the first quarter of 2024, showcasing significant growth and strategic advancements post the integration with NuVasive.The company reported a remarkable 119% increase in sales, reaching $607 million, and a 36% rise in non-GAAP EPS to $0.72.This period marks the first quarter of the combined field organizations of Globus and NuVasive, underscoring a robust integration process aimed at streamlining operations and escalating market reach.

Globus Medical Inc.: How Are Their Strategic Acquisitions and Partnerships Catalyzing Growth? - Major Growth Drivers

<ul><li>Globus Medical, a leading musculoskeletal solutions provider, has reported record revenues of $1.569 billion for the full year 2023, marking a growth of 53% compared to the previous year.</li><li>The strong performance includes four months of sales after its merger with NuVasive.</li><li>This remarkable growth maintained the company's industry-leading profitability, generating a record non-GAAP EPS of $2.32 and an adjusted EBITDA of 30%.</li></ul>

Globus Medical, a leading musculoskeletal solutions provider, has reported record revenues of $1.569 billion for the full year 2023, marking a growth of 53% compared to the previous year.The strong performance includes four months of sales after its merger with NuVasive.This remarkable growth maintained the company's industry-leading profitability, generating a record non-GAAP EPS of $2.32 and an adjusted EBITDA of 30%.

Globus Medical Inc.: Initiation Of Coverage - Increasing Portfolio Range & 3 Critical Growth Factors

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>In November, <a href="https://www.smartkarma.com/entities/orthofix-medical-inc" target="_blank" data-smartkarma-citation="entities:1264:1" rel="noopener">Orthofix International Nv (OFIX US)</a> named Massimo Calafiore as incoming President and CEO. Mr. Calafiore has extensive knowledge in orthopedics and spine, and M&amp;A integration expertise.</li>
<li>Orthofix has performed well and operated smoothly following management transition. In 3Q23, revenue increased 61% YoY on a reported basis and 1% YoY on a pro forma basis to $184M.</li>
<li>The company expects to deliver much higher adjusted profits next year and to exit 2024 cash-flow positive from an estimated $100 million outflow for 2023.</li>
</ul>


In November, Orthofix International Nv (OFIX US) named Massimo Calafiore as incoming President and CEO. Mr. Calafiore has extensive knowledge in orthopedics and spine, and M&amp;A integration expertise.
Orthofix has performed well and operated smoothly following management transition. In 3Q23, revenue increased 61% YoY on a reported basis and 1% YoY on a pro forma basis to $184M.
The company expects to deliver much higher adjusted profits next year and to exit 2024 cash-flow positive from an estimated $100 million outflow for 2023.


Orthofix International (OFIX US): Limited Downside Likely; Looking Ahead to 2024 with New Management

United States

Globus Medical, Inc. is a medical device company. The Company is focused exclusively on the design, development and commercialization of products that promote healing in patients with spine disorders.  Globus Medical's products fall into innovative fusion or disruptive technologies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Globus Medical Inc A (GMED US)

Globus Medical Inc.: How Are Their Strategic Acquisitions and Partnerships Catalyzing Growth? - Major Growth Drivers

Globus Medical recently disclosed its financial results for the first quarter of 2024, showcasing significant growth and strategic advancements...

Baptista Research

Globus Medical Inc.: Initiation Of Coverage - Increasing Portfolio Range & 3 Critical Growth Factors

Globus Medical, a leading musculoskeletal solutions provider, has reported record revenues of $1.569 billion for the full year 2023, marking a...

Baptista Research

Orthofix International (OFIX US): Limited Downside Likely; Looking Ahead to 2024 with New Management

Orthofix has named Massimo Calafiore as its new CEO, who will bring expertise in spine and orthopedics and M&A integration. The company expects...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Globus Medical Inc.: How Are Their Strategic Acquisitions and Partnerships Catalyzing Growth? - Major Growth Drivers

Globus Medical recently disclosed its financial results for the first quarter of 2024, showcasing significant growth and strategic advancements...

Baptista Research

Globus Medical Inc.: Initiation Of Coverage - Increasing Portfolio Range & 3 Critical Growth Factors

Globus Medical, a leading musculoskeletal solutions provider, has reported record revenues of $1.569 billion for the full year 2023, marking a...

Baptista Research

Orthofix International (OFIX US): Limited Downside Likely; Looking Ahead to 2024 with New Management

​Orthofix has named Massimo Calafiore as its new CEO, who will bring expertise in spine and orthopedics and M&A integration. The company expects...

Tina Banerjee

Orthofix has named Massimo Calafiore as its new CEO, who will bring expertise in spine and orthopedics and M&A integration. The company expects...